NASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis $47.03 +0.05 (+0.11%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$47.02 -0.01 (-0.01%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Alkermes Stock (NASDAQ:ALKS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alkermes alerts:Sign Up Key Stats Today's Range$46.10▼$47.4450-Day Range$39.08▼$47.8952-Week Range$27.00▼$55.67Volume1.43 million shsAverage Volume1.83 million shsMarket Capitalization$7.90 billionP/E RatioN/ADividend YieldN/APrice Target$55.73Consensus RatingModerate Buy Company Overview Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults. Alkermes also conducts research and development in neuroscience, seeking to advance treatments for psychiatric and addiction-related disorders. Its commercial activities are centered primarily on the U.S. market.AI Generated. May Contain Errors. Read More Alkermes Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreALKS MarketRank™: 2.557788284735 of 5 starsAlkermes scored higher than 51% of companies evaluated by MarketBeat, and ranked 527th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 1 strong buy rating, 10 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialAlkermes has a consensus price target of $55.73, representing about 18.5% upside from its current price of $47.03.Amount of Analyst CoverageAlkermes has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alkermes' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alkermes are expected to grow in the coming year, from ($0.52) to $0.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is -2,350.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is -2,350.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 4.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.25% of the float of Alkermes has been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 11.25, which indicates bearish sentiment.Change versus previous monthShort interest in Alkermes has recently increased by 3.15%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.99 News SentimentAlkermes has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Alkermes this week, compared to 6 articles on an average week.Search Interest4 people have searched for ALKS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,070,940.00 in company stock.Percentage Held by Insiders4.59% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alkermes' insider trading history. Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALKS Stock News HeadlinesAlkermes Stock Earnings Estimates Lifted by HC WainwrightNovember 13 at 1:43 AM | americanbankingnews.comAlkermes plc (ALKS) - What Are Investment Firms Saying About This Stock?November 11, 2026 | americanbankingnews.comTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.November 15 at 1:00 AM | Traders Agency (Ad)Analysts Have Conflicting Sentiments on These Healthcare Companies: Alkermes (ALKS), Nurix Therapeutics (NRIX) and Beam Therapeutics (BEAM)November 5, 2026 | theglobeandmail.comAlkermes plc 2026 Q3 - Results - Earnings Call PresentationNovember 5, 2026 | seekingalpha.comAlkermes Records Lower Q3 Profit At $16 Mln Despite Higher Product RevenuesNovember 4, 2026 | rttnews.comAlkermes (ALKS) Stock Could Be Overvalued Following ALKS 7290 Trial LaunchNovember 4, 2026 | finance.yahoo.comAlkermes (NASDAQ:ALKS) Stock: Insider David Joseph Gaffin Sells 2,035 SharesNovember 4, 2026 | insidertrades.comSee More Headlines ALKS Stock Analysis - Frequently Asked Questions How have ALKS shares performed this year? Alkermes' stock was trading at $27.98 at the beginning of the year. Since then, ALKS shares have increased by 68.1% and is now trading at $47.03. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) released its earnings results on Wednesday, November, 4th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.17. The firm's revenue for the quarter was up 21.8% compared to the same quarter last year. Read the conference call transcript. Does Alkermes have any subsidiaries? Alkermes subsidiaries include Rodin Therapeutics. Who are Alkermes' major shareholders? Top institutional investors of Alkermes include State Street Corp (6.03%), First Trust Advisors LP (1.18%), Public Sector Pension Investment Board (0.64%) and GW&K Investment Management LLC (0.63%). Insiders that own company stock include David Joseph Gaffin, Shane Cooke, Christian Todd Nichols, Craig C Hopkinson, Christopher I Wright, Cato T Laurencin and Nancy Lynn Md Snyderman. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Bristol Myers Squibb (BMY), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Gilead Sciences (GILD) and Intel (INTC). Company Calendar Last Earnings11/04/2026Today11/15/2026Jefferies Global Healthcare Conference11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ALKS's financial health is in the Red zone, according to TradeSmith. ALKS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,050Year Founded1987Price Target and Rating Average Price Target for Alkermes$55.73 High Price Target$68.00 Low Price Target$36.00 Potential Upside/Downside+18.5%Consensus RatingModerate Buy Rating Score (0-4)2.65 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($0.02) Trailing P/E RatioN/A Forward P/E Ratio130.64 P/E GrowthN/ANet Income$241.66 million Net Margins-0.02% Pretax Margin0.65% Return on Equity0.40% Return on Assets0.19% Debt Debt-to-Equity Ratio0.79 Current Ratio2.42 Quick Ratio2.02 Sales & Book Value Annual Sales$1.48 billion Price / Sales5.35 Cash Flow$1.68 per share Price / Cash Flow28.06 Book Value$11.10 per share Price / Book4.24Miscellaneous Outstanding Shares168,040,000Free Float160,331,000Market Cap$7.90 billion OptionableOptionable Beta0.32 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ALKS) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.